Search results for " renal cell carcinoma."

showing 10 items of 58 documents

Mass Spectrometry Imaging Differentiates Chromophobe Renal Cell Carcinoma and Renal Oncocytoma with High Accuracy

2020

Background: While subtyping of the majority of malignant chromophobe renal cell carcinoma (cRCC) and benign renal oncocytoma (rO) is possible on morphology alone, additional histochemical, immunohistochemical or molecular investigations are required in a subset of cases. As currently used histochemical and immunohistological stains as well as genetic aberrations show considerable overlap in both tumors, additional techniques are required for differential diagnostics. Mass spectrometry imaging (MSI) combining the detection of multiple peptides with information about their localization in tissue may be a suitable technology to overcome this diagnostic challenge. Patients and Methods: Formalin…

0301 basic medicineChromophobe Renal Cell Carcinoma610610 Medicine & healthmass spectrometry imagingBiologyCross-validationMass spectrometry imagingOncocytic renal tumors03 medical and health sciences0302 clinical medicineproteomics10049 Institute of Pathology and Molecular PathologymedicineRenal oncocytomachromophobe renal cell carcinomabusiness.industrymedicine.diseaseLinear discriminant analysisRandom forestSupport vector machine030104 developmental biologyOncology030220 oncology & carcinogenesis2730 OncologyDifferential diagnosisNuclear medicinebusinessrenal oncocytomaResearch PaperJournal of Cancer
researchProduct

Real-World Data on Cabozantinib in Previously Treated Patients with Metastatic Renal Cell Carcinoma: Focus on Sequences and Prognostic Factors

2019

Cabozantinib is approved for the treatment of renal cell carcinoma (RCC). However, prognostic factors are still lacking in this context. The aim of this study was to evaluate prognostic factors in RCC patients treated with second- or third-line cabozantinib. A multicenter retrospective real-world study was conducted, involving 32 worldwide centers. A total of 237 patients with histologically confirmed clear-cell and non-clear-cell RCC who received cabozantinib as second- or third-line therapy for metastatic disease were included. We analyzed overall survival (OS), progression-free survival (PFS) and time-to-strategy failure (TTSF) using Kaplan&ndash

0301 basic medicineOncologyCancer Researchmedicine.medical_specialtyrenal cell carcinomaCabozantinibPrognosiContext (language use)urologic and male genital diseaseslcsh:RC254-282ArticlePazopanib03 medical and health scienceschemistry.chemical_compound0302 clinical medicineRenal cell carcinomacabozantinibInternal medicinemedicineProgression-free survivalCabozantinib; Nivolumab; Prognosis; Real-world data; Renal cell carcinoma; Targeted therapynivolumabreal-world databusiness.industrySunitinibRetrospective cohort studylcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.diseasetargeted therapyAxitinib030104 developmental biologyOncologychemistry030220 oncology & carcinogenesisprognosisbusinessmedicine.drugCancers
researchProduct

MicroRNA-30a-5pme: a novel diagnostic and prognostic biomarker for clear cell renal cell carcinoma in tissue and urine samples

2020

Abstract Background The rising incidence of renal cell carcinomas (RCC) constitutes a significant challenge owing to risk of overtreatment. Because aberrant microRNA (miR) promoter methylation contributes to cancer development, we investigated whether altered miR-30a-5p expression associates with DNA promoter methylation and evaluated the usefulness as clear cell RCC (ccRCC) diagnostic and prognostic markers. Methods Genome-wide methylome and RNA sequencing data from a set of ccRCC and normal tissue samples from The Cancer Genome Atlas (TCGA) database were integrated to identify candidate CpG loci involved in cancer onset. MiR-30a-5p expression and promoter methylation were quantitatively a…

0301 basic medicineOncologyClear cell renal cell carcinomaCancer Researchmedicine.medical_specialty610Urinelcsh:RC254-28203 medical and health sciences0302 clinical medicineInternal medicinemicroRNADiagnosisMedicineDNA methylationReceiver operating characteristicmicroRNAbusiness.industryResearchBiomarkermedicine.diseaselcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensPrognosisLog-rank testClear cell renal cell carcinoma030104 developmental biologyOncologyCpG site030220 oncology & carcinogenesisDNA methylationbusinessClear cellJournal of Experimental & Clinical Cancer Research : CR
researchProduct

Body Mass Index in Patients Treated with Cabozantinib for Advanced Renal Cell Carcinoma: A New Prognostic Factor?

2021

We analyzed the clinical and pathological features of renal cell carcinoma (RCC) patients treated with cabozantinib stratified by body mass index (BMI). We retrospectively collected data from 16 worldwide centers involved in the treatment of RCC. Overall survival (OS) and progression-free survival (PFS) were analyzed using Kaplan&ndash

0301 basic medicinemedicine.medical_specialtyPrognostic factorobesityrenal cell carcinomaMultivariate analysisCabozantinibPrognosiClinical Biochemistrybody mass indexurologic and male genital diseasesGastroenterologyArticle03 medical and health scienceschemistry.chemical_compound0302 clinical medicineRenal cell carcinomacabozantinibInternal medicinemedicineOverall survivalIn patientneoplasmsPathologicallcsh:R5-920real-world databusiness.industrybody mass index; cabozantinib; obesity; prognosis; real-world data; renal cell carcinoma; targeted therapymedicine.diseasetargeted therapyfemale genital diseases and pregnancy complications030104 developmental biologychemistry030220 oncology & carcinogenesisprognosislcsh:Medicine (General)businessBody mass indexDiagnostics
researchProduct

Novel mutations of the MET proto-oncogene in papillary renal carcinomas.

1999

Hereditary papillary renal carcinoma (HPRC) is characterized by multiple, bilateral papillary renal carcinomas. Previously, we demonstrated missense mutations in the tyrosine kinase domain of the MET proto-oncogene in HPRC and a subset of sporadic papillary renal carcinomas. In this study, we screened a large panel of sporadic papillary renal carcinomas and various solid tumors for mutations in the MET proto-oncogene. Summarizing these and previous results, mutations of the MET proto-oncogene were detected in 17/129 sporadic papillary renal carcinomas but not in other solid tumors. We detected five novel missense mutations; three of five mutations were located in the ATP-binding region of t…

AdenomaModels MolecularCancer ResearchProtein ConformationDNA Mutational AnalysisMolecular Sequence DataHereditary Papillary Renal Cell CarcinomaBiologymedicine.disease_causeTransfectionProto-Oncogene MasReceptor tyrosine kinaseMiceAdenosine TriphosphateNeoplastic Syndromes HereditaryProto-OncogenesGeneticsCarcinomamedicineMissense mutationAnimalsHumansPoint MutationAmino Acid SequencePhosphorylationCodonMolecular BiologyKidneyMutationBinding SitesSequence Homology Amino AcidPoint mutation3T3 CellsDNA NeoplasmProto-Oncogene Proteins c-metmedicine.diseaseCarcinoma PapillaryKidney NeoplasmsNeoplasm Proteinsmedicine.anatomical_structureCell Transformation NeoplasticCancer researchbiology.proteinMutagenesis Site-DirectedTyrosine kinaseProtein Processing Post-TranslationalSequence AlignmentOncogene
researchProduct

High proliferation rate and TNM stage but not histomorphological subtype are independent prognostic markers for overall survival in papillary renal c…

2018

Papillary renal cell carcinoma (PRCC) is currently divided in 2 subtypes. We reviewed a large cohort of PRCC and correlated subtype, morphological features and diagnostic marker expression with overall survival (OS) to uncover differences between the 2 subtypes. Three hundred seventy-six renal tumors initially diagnosed as PRCC with clinical and survival data were collected from the participating centers. Two hundred forty-six tumors were classified as PRCC1 (65.4%) and 130 as PRCC2 (34.6%) and graded according to the 2016 World Health Organization/International Society of Urological Pathology grading system. Morphological features (abundant cytoplasm, necrosis, fibrous stroma, foamy macrop…

AdultMale0301 basic medicinemedicine.medical_specialtyPathologyAdolescentPsammoma bodyPathology and Forensic MedicineMetastasisYoung Adult03 medical and health sciences0302 clinical medicineRenal cell carcinomamedicineHumansStage (cooking)ChildCarcinoma Renal CellAgedCell ProliferationNeoplasm StagingAged 80 and overTissue microarrayPapillary renal cell carcinomasbusiness.industryMiddle AgedPrognosismedicine.diseaseKidney Neoplasms030104 developmental biology030220 oncology & carcinogenesisImmunohistochemistryFemaleHistopathologybusinessHuman Pathology
researchProduct

Predictive chromosomal clusters of synchronous and metachronous brain metastases in clear cell renal cell carcinoma

2014

Synchronous (early) and metachronous (late) brain metastasis (BM) events of sporadic clear cell renal cell carcinoma (ccRCC) (n = 148) were retrospectively analyzed using comparative genomic hybridization (CGH). Using oncogenetic tree models and cluster analyses, chromosomal imbalances related to recurrence-free survival until BM (RFS-BM) were analyzed. Losses at 9p and 9q appeared to be hallmarks of metachronous BM events, whereas an absence of detectable chromosomal changes at 3p was often associated with synchronous BM events. Correspondingly, k-means clustering showed that cluster 1 cases generally exhibited low copy number chromosomal changes that did not involve 3p. Cluster 2 cases ha…

AdultMaleCancer ResearchDNA Copy Number VariationsMedizinChromosome 9BiologySporadic Clear Cell Renal Cell Carcinoma03 medical and health sciences0302 clinical medicineGeneticsmedicineHumansCarcinoma Renal CellMolecular BiologyAgedRetrospective StudiesSequence Deletion030304 developmental biologyAged 80 and overChromosome AberrationsGeneticsComparative Genomic Hybridization0303 health sciencesBase SequenceBrain NeoplasmsChromosomeDNA NeoplasmMiddle Agedmedicine.diseaseKidney NeoplasmsClear cell renal cell carcinomaTumor progression030220 oncology & carcinogenesisCancer researchFemaleNeoplasm Recurrence LocalLow copy numberComparative genomic hybridizationBrain metastasisCancer Genetics
researchProduct

Incidence and long-term prognosis of papillary compared to clear cell renal cell carcinoma--a multicentre study.

2012

Abstract Aim of the study Papillary renal cell carcinoma (pRCC) is the second most common subtype of RCC after the conventional clear cell type (cRCC). However, its characteristics and prognosis have been less intensively investigated. The aim of our study was to examine the tumour characteristics and long-term prognosis of pRCC compared to clear cell RCC (cRCC). Methods In total, 4941 evaluable patients were subjected to either radical nephrectomy or nephron-sparing surgery for pRCC or cRCC at five centres in Germany (University Hospitals of Hannover, Homburg/Saar, Mainz, Ulm and Marburg) between 1990 and 2010. Results pRCC ( n  = 565) and cRCC ( n  = 4376) patients were comparable with re…

AdultMaleCancer Researchmedicine.medical_specialtyPathologymedicine.medical_treatmentGastroenterologyYoung AdultInternal medicineGermanyCarcinomaMedicineHumansSurvival rateCarcinoma Renal CellAgedRetrospective StudiesAged 80 and overPapillary renal cell carcinomasbusiness.industryIncidenceMiddle Agedmedicine.diseasePrognosisNephrectomyKidney NeoplasmsSurvival RateClear cell renal cell carcinomaOncologyClear cell carcinomaFemalebusinessKidney cancerClear cellEuropean journal of cancer (Oxford, England : 1990)
researchProduct

Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas.

1998

Hereditary papillary renal carcinoma (HPRC) is a recently recognized form of inherited kidney cancer characterized by a predisposition to develop multiple, bilateral papillary renal tumours. The pattern of inheritance of HPRC is consistent with autosomal dominant transmission with reduced penetrance. HPRC is histologically and genetically distinct from two other causes of inherited renal carcinoma, von Hippel-Lindau disease (VHL) and the chromosome translocation (3;8). Malignant papillary renal carcinomas are characterized by trisomy of chromosomes 7, 16 and 17, and in men, by loss of the Y chromosome. Inherited and sporadic clear cell renal carcinomas are characterized by inactivation of b…

AdultMaleGenetic LinkageUrologyMolecular Sequence DataHereditary Papillary Renal Cell CarcinomaChromosomal translocationBiologyurologic and male genital diseasesY chromosomemedicine.disease_causeProto-Oncogene MasGermlineGermline mutationGeneticsmedicineMissense mutationHumansAmino Acid SequenceCarcinoma Renal CellGerm-Line MutationAgedKidneyMutationBinding SitesSequence Homology Amino Acidbusiness.industryReceptor Protein-Tyrosine KinasesMiddle AgedProtein-Tyrosine KinasesProto-Oncogene Proteins c-metmedicine.diseasePenetranceCarcinoma PapillaryKidney NeoplasmsPedigreemedicine.anatomical_structureProto-Oncogene Proteins c-metMutationCancer researchHereditary leiomyomatosis and renal cell carcinomaFemaleTrisomybusinessKidney cancerChromosomes Human Pair 7Nature genetics
researchProduct

Human chromophobe cell renal carcinoma

1985

Twelve renal cell carcinomas composed of "chromophobe" cells are described. This is the first report of renal chromophobe cell tumors in humans neoplasms of this cell type having been described previously only in experimentally induced adenomas in animals. By light microscopy chromophobe cells have slightly opaque or finely reticular cytoplasm when stained with haematoxylin and eosin. They may be distinguished from the clear cells of hypernephroid renal cell carcinomas by the strongly positive reaction of their cytoplasm with Hale's (1946) colloidal iron method and the weaker positive reaction with alcian blue. Vesicular structures, often containing internal vesicles, and possibly derived f…

AdultMaleKidneyPathologymedicine.medical_specialtyCell typeChromophobe Renal Cell CarcinomaCellChromophobe cellMiddle AgedBiologyurologic and male genital diseasesmedicine.diseaseKidney NeoplasmsMicroscopy Electronstomatognathic diseasesmedicine.anatomical_structureRenal cell carcinomamedicineHumansChromophobe cell renal carcinomaFemaleCarcinoma Renal CellAgedVirchows Archiv B Cell Pathology Including Molecular Pathology
researchProduct